X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2023 Earnings Conference Call March 21, 2024 8:30 AM ET

Company Participants

Dan Ferry - LifeSci Advisors, IR
Dr. Paula Ragan - Chief Executive Officer
Adam Mostafa - Chief Financial Officer
Mark Baldry - Chief Commercial Officer
Dr. Christophe Arbet-Engels - Chief Medical Officer
Mary DiBiase - Chief Operating Officer
Art Taveras - Chief Scientific Officer

Conference Call Participants

Kristen Kluska - Cantor Fitzgerald
Ed Tenthoff - Piper Sandler
Sean Lee - H.C. Wainwright
Stephen Willey - Stifel

Operator

Greetings. And welcome to the X4 Pharmaceuticals Fourth Quarter and Full Year 2023 Financial and Operating Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Dan Ferry from LifeSci Advisors. Please begin.

Dan Ferry

Thank you, Operator, and good morning, everyone. Presenting on today’s call will be X4’s Chief Executive Officer, Dr. Paula Ragan; and Chief Financial Officer, Adam Mostafa. Following prepared remarks by each, we will open the call to your questions and we’ll be joined by Chief Commercial Officer, Mark Baldry; Chief Medical Officer, Dr. Christophe Arbet-Engels; Chief Operating Officer, Mary DiBiase; and Chief Scientific Officer, Art Taveras.

As a reminder, on today’s call, the company will be making forward-looking statements regarding regulatory and product development plans, as well as research activities. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. Description of these risks can be found in X4’s most recent filings with the SEC, including this year’s Form 10-K, which is expected to be filed after market close today.

I’d now like to turn the call over to X4’s President and CEO, Dr. Paula Ragan. Paula?

Dr. Paula Ragan

Thanks, Dan. Good morning, everyone, and thank you for joining us on the call today. As we look ahead to 2024, we thought we’d take the time to reflect on all that we’ve accomplished over the past year, milestones that have set the stage for what we expect will be an incredibly exciting and truly transformative year for X4, a year where we aim to become a fully integrated research, development and commercialization company with the goal of delivering new options for rare disease patients.

Throughout 2023, we hit several major milestones. Most importantly, submission and acceptance under FDA’s priority review process of our NDA seeking approval of mavorixafor, our oral targeted CXCR4 antagonist for the treatment of WHIM syndrome.